Astellas Oncology
Menu

News & Events Highlights

A selection of Astellas Oncology news and events highlights, updated quarterly.

Astellas Contacts

For Media
Tyler Marciniak
(847) 736-7145
tyler.marciniak@astellas.com
For Investors
So Sekine
+81-3-3244-3202
sou.sekine@astellas.com

News Highlights

  • Astellas Names Shontelle Dodson Senior Vice President and Head of Medical Affairs Americas

    NORTHBROOK, Ill., May 11, 2017 — Astellas today announced the promotion of Shontelle Dodson, Pharm.D., to senior vice president and head of Medical Affairs Americas, effective May 15, 2017. Dodson previously served as vice president of Medical Excellence within the global Medical Affairs organization.

    Read more...
  • Astellas Announces Decision to Discontinue ASP8273 Treatment Arm and Close Randomization for Clinical Study Protocol 8273-CL-0302

    TOKYO, May 10, 2017 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the 1st line treatment metastatic or advanced unresectable non-small cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutation.

    Read more...
  • Astellas Recognized as a Top Employer by Forbes Magazine for the Third Consecutive Year

    NORTHBROOK, Ill., May 9, 2017 — Today, Astellas was named one of America's top midsize workplaces by Forbes Magazine. This is Astellas' third consecutive appearance on the Forbes Best Employers list.

    Read more...
  • Astellas Announces Key Leadership Promotions in Development Organization

    NORTHBROOK, Ill., April 28, 2017 / PRNewswire / — Astellas today announced three recent senior-level promotions within its Development organization.

    Read more...
  • Astellas Completes Acquisition of Ganymed Pharmaceuticals

    TOKYO, Dec. 21, 2016 / PRNewswire / — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG ("Ganymed"), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016.

    Read more...
  • FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

    TOKYO and NEW YORK, Oct. 21, 2016 / PRNewswire / -- Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study.

    Read more...
  • Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care

    NORTHBROOK, Ill., Oct. 11, 2016 / PRNewswire / -- Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve the cancer care experience for patients, caregivers and their loved ones – during the European Society of Medical Oncology (ESMO) Annual Congress in Copenhagen, Denmark Friday, October 7.

    Read more...
  • Astellas Expands Leadership in Oncology Clinical Development

    NORTHBROOK, Ill., Oct. 5, 2016 / PRNewswire / -- Astellas today announced the appointment of Steven E. Benner, M.D., as senior vice president and Therapeutic Area Head for Oncology, and the promotion of Anne Keating, Pharm. D., to vice president of Clinical Science for Oncology, within the company's Development organization.

    Read more...
  • Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting

    TOKYO and CHICAGO, June 6, 2016 / PRNewswire / -- Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.

    Read more...
  • Astellas Oncology Announces Data to be Presented at 2016 ASCO Annual Meeting

    NORTHBROOK, Ill., May 19, 2016 / PRNewswire / — Astellas announced today a selection of abstracts it will present on early phase data for ASP8273 in patients with EGFR mutation positive non-small cell lung cancer (NCSLC), gilteritinib pharmacokinetics and pharmacodynamics in patients with relapsed or refractory acute myeloid leukemia and two investigational antibody drug conjugates in patients with metastatic urothelial cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 in Chicago.

    Read more...
  • Astellas Oncology C3 Prize™ to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants

    BOSTON, April 26, 2016 / PRNewswire - USNewswire / — Astellas Pharma Inc. (TSE: 4503) announced today the launch of the C3 Prize™, a challenge designed to inspire non-medicine innovations that improve the cancer care experience for patients, caregivers and loved ones.

    Read more...
  • CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)

    TOKYO and SAN FRANCISCO, April 7, 2016 / PRNewswire / — Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzalutamide versus bicalutamide in the European label for XTANDI® (enzalutamide) capsules.

    Read more...
  • Statement from Astellas regarding availability of XTANDI — March 29, 2016

    Read more...
  • Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

    TOKYO and SAN FRANCISCO, March 24, 2016 / PRNewswire / — Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that the ARCHES (AR Inhibition with ChemoHormonal Therapy in Men with MEtastatic Castrate Sensitive Prostate Cancer) Phase III registrational trial, which will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients, has been initiated and the first patient has been randomized.

    Read more...
  • FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

    TOKYO and SAN FRANCISCO, Feb. 22, 2016 / PRNewswire / — Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) that they have submitted for XTANDI® (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication.

    Read more...
  • Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer

    NORTHBROOK, Ill. and SAN FRANCISCO, Jan. 26, 2016 / PRNewswire / — Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc. (TSE: 4503), and Medivation, Inc. (Nasdaq: MDVN) today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

    Read more...
  • Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer

    NORTHBROOK, Ill. and SAN FRANCISCO, Jan. 13, 2016 / PRNewswire / — Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN), today announced that results from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC) were published in the Lancet Oncology.

    Read more...
  • Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy

    Bellicum obtains rights to develop adoptive cell therapies targeting tumors expressing PSCA; Astellas or Agensys retains option for commercial rights in Japan.

    Read more...
  • Astellas Announces Updated Data from the Phase 1/2 CHRYSALIS Trial for Gilteritinib (ASP2215) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

    NORTHBROOK, Ill., Dec. 6, 2015 / PRNewswire / — Astellas US, LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that updated data from the Phase 1/2 CHRYSALIS trial evaluating the safety, tolerability and antileukemic activity of gilteritinib (ASP2215), an orally-administered inhibitor of FLT3/AXL in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML), were presented during an oral scientific session at the American Society of Hematology (ASH) 2015 annual meeting in Orlando.

    Read more...
  • Astellas Inititaties Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia Patients

    TOKYO, Oct. 28, 2015 / PRNewswire / — Astellas Pharma Inc. (TSE: 4503) today announced dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib (ASP2215) versus salvage chemotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary endpoint of the trial is overall survival (OS).

    Read more...
  • #pass4prostate Challenge Raises Prostate Cancer Awareness and Research Funds

    Social media campaign to rally supporters around the world in tackling the second most common cancer among men

    Read more...
  • New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting

    TOKYO and NORTHBROOK, Ill., June 1, 2015 / PRNewswire / — Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    Read more...
  • Astellas And Medivation Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry

    TRUMPET Study Seeks Insights to Better Understand Treatment Regimens, Quality of Life Outcomes for Patients Living with Castration-Resistant Prostate Cancer and Their Caregivers

    Read more...
  • Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML)

    • Results from Phase 1/2 trial investigating drug candidate for rare, aggressive blood cancer announced at American Society of Clinical Oncology annual meeting; Phase 3 trial planned for late 2015.
    • Abstract is one of several Astellas Oncology data presentations scheduled for the ASCO annual meeting

    Read more...

Event Highlights

  • 2 – 6 June 2017
    Chicago, Illinois
    ASCO (American Society of Clinical Oncology) Annual Meeting
    Visit us at ASCO
  • 22 – 25 June 2017
    Madrid, Spain
    EHA (European Hematology Association) Congress
    Visit us at EHA
  • 8 – 12 September 2017
    Madrid, Spain
    ESMO (European Society of Medical Oncology) Congress
    Visit us at ESMO
  • 9 – 12 December 2017
    Atlanta, Georgia
    ASH (American Society of Hematology) Annual Meeting
    Visit us at ASH